Jordi Gich1, Jordi Freixanet2, Rafael García2, Joan Carles Vilanova3, David Genís1, Yolanda Silva1, Xavier Montalban4, Lluís Ramió-Torrentà5. 1. Neurology Department, Dr Josep Trueta University Hospital, Girona, Spain/Girona Biomedical Research Institute (IDIBGI), Girona, Spain. 2. Institute of Informatics and Applications, University of Girona, Girona, Spain. 3. Radiology Service, Clínica Girona, Girona, Spain. 4. Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain. 5. Neurology Department, Dr Josep Trueta University Hospital, Girona, Spain/Girona Biomedical Research Institute (IDIBGI), Girona, Spain llramio.girona.ics@gencat.cat.
Abstract
BACKGROUND:MS-Line! was created to provide an effective treatment for cognitive impairment in multiple sclerosis (MS) patients. OBJECTIVE: To assess the efficacy of MS-Line!. METHODS: A randomized, controlled, single-blind, 6-month pilot study. Patients were randomly assigned to an experimental group (cognitive rehabilitation with the programme) or to a control group (no cognitive rehabilitation). Randomization was stratified by cognitive impairment level. Cognitive assessment included: selective reminding test, 10/36 spatial recall test (10/36 SPART), symbol digit modalities test, paced auditory serial addition test, word list generation (WLG), FAS test, subtests of WAIS-III, Boston naming test (BNT), and trail making test (TMT). RESULTS: Forty-three patients (22 in the experimental group, 21 in the control group) were analyzed. Covariance analysis showed significant differences in 10/36 SPART (P=0.0002), 10/36 SPART delayed recall (P=0.0021), WLG (P=0.0123), LNS (P=0.0413), BNT (P=0.0007) and TMT-A (P=0.010) scores between groups. CONCLUSIONS: The study showed a significant improvement related to learning and visual memory, executive functions, attention and information processing speed, and naming ability in those patients who received cognitive rehabilitation. The results suggest that MS-Line! is effective in improving cognitive impairment in MS patients.
RCT Entities:
BACKGROUND: MS-Line! was created to provide an effective treatment for cognitive impairment in multiple sclerosis (MS) patients. OBJECTIVE: To assess the efficacy of MS-Line!. METHODS: A randomized, controlled, single-blind, 6-month pilot study. Patients were randomly assigned to an experimental group (cognitive rehabilitation with the programme) or to a control group (no cognitive rehabilitation). Randomization was stratified by cognitive impairment level. Cognitive assessment included: selective reminding test, 10/36 spatial recall test (10/36 SPART), symbol digit modalities test, paced auditory serial addition test, word list generation (WLG), FAS test, subtests of WAIS-III, Boston naming test (BNT), and trail making test (TMT). RESULTS: Forty-three patients (22 in the experimental group, 21 in the control group) were analyzed. Covariance analysis showed significant differences in 10/36 SPART (P=0.0002), 10/36 SPART delayed recall (P=0.0021), WLG (P=0.0123), LNS (P=0.0413), BNT (P=0.0007) and TMT-A (P=0.010) scores between groups. CONCLUSIONS: The study showed a significant improvement related to learning and visual memory, executive functions, attention and information processing speed, and naming ability in those patients who received cognitive rehabilitation. The results suggest that MS-Line! is effective in improving cognitive impairment in MS patients.
Authors: Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair Journal: Health Technol Assess Date: 2020-01 Impact factor: 4.014
Authors: Lauren A Taylor; Jacqueline R Mhizha-Murira; Laura Smith; Kristy-Jane Potter; Dana Wong; Nikos Evangelou; Nadina B Lincoln; Roshan das Nair Journal: Cochrane Database Syst Rev Date: 2021-10-18
Authors: Jessica Podda; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto Journal: Mult Scler Date: 2020-10-13 Impact factor: 5.855